Drugs / Pirepemat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05258071 | Jun 2022 → Dec 2024 | Parkinson disease | Integrative Research Laboratories AB | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-03-28 | Integrative Research Laboratories AB | Results IRLAB provides additional efficacy data from the Phase IIb study of pirepemat in patients with Parkinson’s disease irlab.se ↗
The analysis reveals that in a medium plasma concentration range, pirepemat reduced the fall rate by as much as 51.5% after three months of treatment. |
| 2025-03-05 | Integrative Research Laboratories AB | Results IRLAB reports topline results from a Phase IIb study of pirepemat in patients with Parkinson’s disease irlab.se ↗
The results show that treatment with pirepemat (600 mg daily) reduced the fall rate by 42 percent among individuals with Parkinson’s disease; however, this effect did not reach statistical significance compared to placebo. |
| 2024-09-18 | Integrative Research Laboratories AB | Regulatory IRLAB granted additional patent for its drug candidate pirepemat expanding the patent protection in the US irlab.se ↗
IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that a new patent has been granted in the US covering a salt of the drug candidate pirepemat. |
| 2023-07-17 | Integrative Research Laboratories AB | Results IRLAB’s Phase IIb study with pirepemat passes DSMB safety review with unanimous recommendation to continue the ongoing Phase IIb study irlab.se ↗
After this review, the DSMB unanimously recommend that the Phase IIb study continues according to the approved study protocol without modifications. |
| 2021-12-21 | Integrative Research Laboratories AB | Regulatory IRLAB obtains regulatory approval to conduct Phase IIb study with pirepemat – one step closer to improving balance and reducing fall injuries for people living with Parkinson’s disease irlab.se ↗
IRLAB receives regulatory approval from the Swedish MPA for conducting a Phase IIb study with the investigational drug candidate pirepemat. |
| 2021-06-15 | Integrative Research Laboratories AB | Results IRLAB’s drug candidate pirepemat’s Phase I data published in scientific journal CPDD irlab.se ↗
It was concluded that pirepemat was safe and well-tolerated in healthy male volunteers. |
| 2020-09-10 | Integrative Research Laboratories AB | Results IRLAB’s drug candidate pirepemat featured on cover of top-tier journal JPET irlab.se ↗
This owing to the publication of a scientific paper in the journal, where the distinctive pharmacological profile of pirepemat is reported. |
| 2020-08-03 | Integrative Research Laboratories AB | Regulatory IRLAB’s IRL752 is proposed pirepemat as a unique INN by WHO irlab.se ↗
IRLAB announced today that the World Health Organization (WHO) has proposed the name pirepemat as the International Nonproprietary Name (INN) for the company’s drug candidate IRL752, which is in development for decreasing the risk of falling in patients with Parkinson’s disease. |
All press releases naming this drug 16 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pirepemat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05258071 ↗ |
| Known as | IRL-752 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095193 ↗ |
| Modality | Small molecule | — CHEMBL5095193 ↗ |
| Route | Oral | “Oral use” NCT05258071 ↗ |